Next Generation Sequencing (NGS) Markets 2015 (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Platforms, Applications, Brand Ownership and Other Trends)
No business planner in biotechnology or diagnostic equipment or services can ignore the trend of sequencing, and particularly next-generation sequencing. This technology has enabled a wide scope of research and genetic analysis. The promise of DNA sequencing has attracted many companies, researchers, and investors. DNA sequencing has already become a large market, and clinical applications of DNA sequencing are being developed and commercialized. More than ever, marketers of advanced equipment and those investing in those companies need a resource to identify the specific developments in sequencing.
This report, Next-Generation Sequencing Markets (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Trends, Platforms, Applications, Brand Ownership) provides evidence of the promise and current excitement in the DNA sequencing market.
Tracking the Path of Sequencing to the Clinical Lab
Many improvements in sequencing technology are needed in order to make sequencing-based diagnostic tests widely available and used by all physicians, though DNA sequencing has successfully penetrated the research market. Applications of next generation sequencing in clinical laboratories and companies with CLIA-certified laboratories will continue to grow. The first next generation sequencing system and IVD tests have been cleared by the FDA, and more will follow. Some next generation sequencing companies are starting to develop and commercialize kits that can be produced and sold to clinical laboratories following the traditional in vitro diagnostic (IVD) model.
Reasons for Optimism
Over the years, the DNA sequencing field has gone through periods of excitement (referred to as hype) by some, followed by periods of disappointment as the hoped for advances have not materialized as quickly as hoped or promised.
The promise of DNA sequencing has attracted many companies, researchers, investors, and others. DNA sequencing has already become a large market, and clinical applications of DNA sequencing are being developed and commercialized. Evidence of the promise and current excitement with DNA sequencing can be seen with many recent events:
The DNA sequencing market is growing rapidly. In October 2014, market leader Illumina raised the company’s full year 2014 guidance for investors to a revenue growth for the company of approximately 30% over the previous year.
Roche and Foundation Medicine announced an agreement that is worth up to $1.2 billion. Roche agreed to acquire a majority interest in Foundation Medicine for approximately $780 million. Roche also agreed to invest $250 million in Foundation Medicine, and to fund potentially more than $150 million of R&D
Companies are raising money: In just the first part of January 2015, In addition to Roche’s investment in Foundation Medicine, 10X Genomics closed a $55.5 million Series B financing and Invitae filed for an initial public offering, These follow a busy 2014 year that saw many investments in next generation sequencing companies and companies with products or services related to next generation sequencing.
Agreements with pharmaceutical companies: Companies in the pharmaceutical industry have recognized the potential benefits of next generation sequencing as a research and development tool. During just part of 2015, Genentech announced two agreements, and Pfizer announced one.
Sequencing companies are starting to develop and commercialize kits that can be produced and sold to clinical laboratories following the traditional in vitro diagnostic (IVD) model. Illumina’s MiSeqDx was the first cleared in vitro diagnostic (IVD) next generation sequencing system. MiSeqDx is also CE marked, and FDA-cleared tests are currently available on this platform.
These are just selected highlights of recent activities in this rapidly changing market. Because of these trends, Kalorama expects the market to grow from its current size of 2.2 billion to 5.6 billion. The entire market is broken out in detail in Kalorama’s Next Generation Sequencing Markets.
This Informative Analysis Helps You Track These Developments, with Reliable Market Estimates
The report provides the world markets for next generation sequencing in U.S. dollars for 2014 to 2018. As part of its analysis, the following data points are provided.
Who's Doing What In Sequencing: Superior Company Profiling
Competitor participation is an important part of the shaping of this market and the report devotes considerable detail to competitive analysis. Driven by the promise of clinical diagnostic applications, the DNA sequencing market is growing rapidly and companies are raising money. In early 2015 and throughout a busy 2014 there were many investments in next generation sequencing companies and companies with products or services related to next generation sequencing. Pharmaceutical companies, for example, have recognized the potential benefits of next generation sequencing as a research and development tool. The report provides product information and financial information for over 100 companies that are involved in next generation sequencing including:
This report, Next-Generation Sequencing Markets (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Trends, Platforms, Applications, Brand Ownership) provides evidence of the promise and current excitement in the DNA sequencing market.
Tracking the Path of Sequencing to the Clinical Lab
Many improvements in sequencing technology are needed in order to make sequencing-based diagnostic tests widely available and used by all physicians, though DNA sequencing has successfully penetrated the research market. Applications of next generation sequencing in clinical laboratories and companies with CLIA-certified laboratories will continue to grow. The first next generation sequencing system and IVD tests have been cleared by the FDA, and more will follow. Some next generation sequencing companies are starting to develop and commercialize kits that can be produced and sold to clinical laboratories following the traditional in vitro diagnostic (IVD) model.
Reasons for Optimism
Over the years, the DNA sequencing field has gone through periods of excitement (referred to as hype) by some, followed by periods of disappointment as the hoped for advances have not materialized as quickly as hoped or promised.
The promise of DNA sequencing has attracted many companies, researchers, investors, and others. DNA sequencing has already become a large market, and clinical applications of DNA sequencing are being developed and commercialized. Evidence of the promise and current excitement with DNA sequencing can be seen with many recent events:
The DNA sequencing market is growing rapidly. In October 2014, market leader Illumina raised the company’s full year 2014 guidance for investors to a revenue growth for the company of approximately 30% over the previous year.
Roche and Foundation Medicine announced an agreement that is worth up to $1.2 billion. Roche agreed to acquire a majority interest in Foundation Medicine for approximately $780 million. Roche also agreed to invest $250 million in Foundation Medicine, and to fund potentially more than $150 million of R&D
Companies are raising money: In just the first part of January 2015, In addition to Roche’s investment in Foundation Medicine, 10X Genomics closed a $55.5 million Series B financing and Invitae filed for an initial public offering, These follow a busy 2014 year that saw many investments in next generation sequencing companies and companies with products or services related to next generation sequencing.
Agreements with pharmaceutical companies: Companies in the pharmaceutical industry have recognized the potential benefits of next generation sequencing as a research and development tool. During just part of 2015, Genentech announced two agreements, and Pfizer announced one.
Sequencing companies are starting to develop and commercialize kits that can be produced and sold to clinical laboratories following the traditional in vitro diagnostic (IVD) model. Illumina’s MiSeqDx was the first cleared in vitro diagnostic (IVD) next generation sequencing system. MiSeqDx is also CE marked, and FDA-cleared tests are currently available on this platform.
These are just selected highlights of recent activities in this rapidly changing market. Because of these trends, Kalorama expects the market to grow from its current size of 2.2 billion to 5.6 billion. The entire market is broken out in detail in Kalorama’s Next Generation Sequencing Markets.
This Informative Analysis Helps You Track These Developments, with Reliable Market Estimates
The report provides the world markets for next generation sequencing in U.S. dollars for 2014 to 2018. As part of its analysis, the following data points are provided.
- DNA Sequencing Systems Market Size and Forecast
- DNA Sequencing Consumables Market, Size and Forecast
- DNA Sequencing Services Market, Size and Forecast
- Sequencing Market – Geographical Distribution (US, Europe, Asia, ROW)
- Market Share by Major Competitor
- Brand Ownership by Platform
- DNA Sequencing Market – Research versus Clinical Applications
Who's Doing What In Sequencing: Superior Company Profiling
Competitor participation is an important part of the shaping of this market and the report devotes considerable detail to competitive analysis. Driven by the promise of clinical diagnostic applications, the DNA sequencing market is growing rapidly and companies are raising money. In early 2015 and throughout a busy 2014 there were many investments in next generation sequencing companies and companies with products or services related to next generation sequencing. Pharmaceutical companies, for example, have recognized the potential benefits of next generation sequencing as a research and development tool. The report provides product information and financial information for over 100 companies that are involved in next generation sequencing including:
- 10X Genomics
- 23andMe, Inc.
- Adaptive Biotechnologies Corporation
- Admera Health (A GENEWIZ Company)
- Advanced Biological Laboratories, S.A.
- Agilent Technologies Inc.
- AltheaDx Diagnostics, Inc.
- Ambry Genetics Corp.
- Aperiomics, Inc.
- Appistry, Inc.
- Asuragen, Inc.
- Athena Diagnostics, Inc. (A Quest Diagnostics Business)
- Base4 Innovation Ltd.
- Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
- BGI-Shenzhen
- Bina Technologies, Inc. (Acquired by Roche)
- BioDiscovery, Inc.
- Bioinnovation Solutions SA
- Biomatters Ltd.
- bioMérieux SA
- bioTheranostics (A bioMérieux Company)
- Cancer Genetics, Inc.
- CareDx, Inc.
- Caris Life Sciences
- Chronix Biomedical, Inc.
- CLC bio (A QIAGEN Company)
- Complete Genomics (A BGI Company)
- Courtagen Life Sciences, Inc.
- Cypher Genomics, Inc.
- DioGenix, Inc.
- DNA Electronics Ltd.
- DNASTAR, Inc.
- Eurofins Genomics
- Eurofins MWG Operon Inc. (A Eurofins Genomics Company)
- Expression Analysis, Inc. (A Quintiles Company)
- Fluidigm Corporation
- Foundation Medicine, Inc.
- GATC Biotech AG
- GenapSys
- GenDx
- Gene by Gene, Ltd.
- Genection, Inc. (An Invivoscribe Company)
- GeneDx
- GeneInsight, Inc.
- GENEWIZ Inc.
- Genia Technologies, Inc. (Acquired by Roche)
- GenoLogics Life Sciences Software
- Genomic Diagnostics Technologies
- GenomOncology
- Genoptix (A Novartis Company)
- GigaGen, Inc.
- GnuBIO, Inc. (Acquired by Bio-Rad Laboratories, Inc.)
- Good Start Genetics, Inc.
- HTG Molecular Diagnostics
- Human Longevity, Inc.
- Igenbio, Inc.
- Illumina, Inc.
- Innovations Exchange Pte Ltd (INEX)
- iGene Diagnostics Pte Ltd (an INEX Company)
- Insight Genetics, Inc.
- InSilixa, Inc.
- Intel Corporation
- Intelligent Bio-Systems, Inc. (A QIAGEN Company)
- Invivoscribe Technologies, Inc.
- iRepertoire, Inc.
- Knome Inc.
- Laboratory Corporation of America (LabCorp)
- LaserGen, Inc.
- LifeCodexx AG (Subsidiary of GATC Biotech AG)
- Life Technologies Corporation (Acquired by Thermo Fischer Scientific Inc.)
- Mayo Medical Laboratories and Mayo Clinic
- MolecularMD Corporation
- Multiplicom NV
- Nabsys, Inc.
- Natera, Inc.
- NeoGenomics, Inc./NeoGenomics Laboratories
- NetBio, Inc.
- NewGene Ltd.
- NextCODE Health
- NobleGen Biosciences, Inc.
- N-of-One, Inc.
- OncoDNA SA
- OncoPlex Diagnostics (OncoPlexDx)
- Oncospire Genomics
- One Lambda, Inc. (A Thermo Fisher Scientific Brand)
- Oxford Gene Technology
- Oxford Nanopore Technologies Ltd.
- Pacific Biosciences
- Parabase Genomics
- Pathway Genomics Corporation
- PerkinElmer, Inc.
- Personal Genome Diagnostics, Inc.
- Personalis, Inc.
- PicoSeq
- Population Genetics Technologies Ltd.
- QIAGEN N.V.
- QuantuMDx Group
- Quest Diagnostics
- RainDance Technologies, Inc.
- Response Genetics, Inc.
- Roche
- SeqLL, LLC
- Sequenta, Inc.
- Siemens Healthcare Diagnostics
- Siemens
- Sirona Genomics
- SoftGenetics, LLC
- Stratos Genomics Inc.
- Swift Biosciences, Inc.
- Symbiodx
- Sysmex Inostics GmbH
- Thermo Fisher Scientific, Inc.
- Vela Diagnostics
- WaferGen Biosystems, Inc.
- ZS Genetics, Inc.
ONE: EXECUTIVE SUMMARY
Overview
Scope and Methodology
Market Overview
Prognosis for Growth of the DNA Sequencing Market
TWO: INTRODUCTION
Overview and History of DNA Sequencing
Point-of-View
THREE: SEQUENCING TECHNOLOGY
Sanger Sequencing
Next-Generation Sequencing
Massively Parallel Signature Sequencing (MPSS)
Pyrosequencing
454 TECHNOLOGY
Sequencing by Synthesis (SBS)
Supported Oligonucleotide Ligation and Detection (SOLiD)
Ion Torrent Sequencing
True Single Molecule Sequencing (tSMS)
Single Molecule Real Time (SMRT) Sequencing
DNA Nanoball Sequencing
Nanopore Sequencing
Other Sequencing Technologies
Sample Preparation
Information Technology
Sample-to-Answer Workflows or Platforms
FOUR: SEQUENCING APPLICATIONS
Research, Drug Discovery and Development
Diagnostic Applications of Sequencing
Cancer Diagnostics
Genetic Analysis – Inherited Disorders, Prenatal Diagnostics, Postnatal Diagnostics
Infectious Disease Diagnostics
Human Leukocyte Antigen (HLA) Testing
Other Diagnostic Applications of Sequencing
Direct-to-Consumer Genetic Testing Industry
FIVE: DEALS – SEQUENCING COMPANIES
Investments and Financing Agreements for Sequencing Companies
Agreements with Other Companies
Acquisitions of Sequencing Companies
Selected Other Agreements
SIX: APPLYING SEQUENCING TO DIAGNOSTICS – MARKET DRIVERS AND CHALLENGES
Overcoming Technology Hurdles – Sample Preparation and Data Analysis
Next Generation Sequencing Market Drivers
Issues and Hurdles Faced by Companies Selling to the Research Market
Issues and Hurdles Faced by Companies in the Diagnostics Market
Future Prospects
SEVEN: DNA SEQUENCING MARKET ANALYSIS
DNA Sequencing Market Overview
Sequencing Market – Geographical Distribution
Brand Ownership
DNA Sequencing Market – Research versus Clinical Applications
EIGHT: COMPANY PROFILES: NEXT GENERATION SEQUENCING COMPANIES
10X GENOMICS
23ANDME, INC.
Adaptive Biotechnologies Corporation
Admera Health (A GENEWIZ Company)
Advanced Biological Laboratories, S.A
Agilent Technologies Inc.
Recent Revenue History
Company Overview
AltheaDx Diagnostics, Inc.
Ambry Genetics Corp.
Aperiomics, Inc.
Appistry, Inc.
Asuragen, Inc.
Diagnostic Products
Genomic Services
Clinical Lab
Companion Diagnostics
Athena Diagnostics, Inc. (A Quest Diagnostics Business)
Base4 Innovation Ltd
Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
Recent Revenue History
Company Overview
Next-Generation Sequencing - Sample Prep
Beckman Coulter Genomics
BGI-Shenzhen
Bina Technologies, Inc. (Acquired by Roche)
BioDiscovery, Inc.
Bioinnovation Solutions SA
Biomatters Ltd.
bioMérieux SA
Recent Revenue History
Company Overview
bioTheranostics (A bioMérieux Company)
Cancer Genetics, Inc.
Recent Revenue History
Company Overview
CareDx, Inc.
Recent Revenue History
Company Overview
Caris Life Sciences
Chronix Biomedical, Inc.
CLC bio (A QIAGEN Company)
Complete Genomics (A BGI Company)
Courtagen Life Sciences, Inc.
Cypher Genomics, Inc
DioGenix, Inc.
DNA Electronics Ltd.
DNASTAR, Inc.
Eurofins Genomics
Eurofins MWG Operon Inc. (A Eurofins Genomics Company)
Expression Analysis, Inc. (A Quintiles Company)
Fluidigm Corporation
Recent Revenue History
Company Overview
Foundation Medicine, Inc.
Recent Revenue History
Company Overview
GATC Biotech AG
GenapSys
GenDx
Gene by Gene, Ltd.
Genection, Inc. (An Invivoscribe Company)
GeneDx
GeneInsight, Inc.
GENEWIZ Inc.
Genia Technologies, Inc. (Acquired by Roche)
GenoLogics Life Sciences Software
Genomic Diagnostics Technologies
GenomOncology
Genoptix (A Novartis Company)
GigaGen, Inc.
GnuBIO, Inc. (Acquired by Bio-Rad Laboratories, Inc.)
Good Start Genetics, Inc.
HTG Molecular Diagnostics
Human Longevity, Inc.
Igenbio, Inc.
Illumina, Inc.
Recent Revenue History
Company Overview
Innovations Exchange Pte Ltd (INEX)
iGene Diagnostics Pte Ltd (an INEX Company)
Insight Genetics, Inc.
InSilixa, Inc.
Intel Corporation
Recent Revenue History
Company Overview
Intelligent Bio-Systems, Inc. (A QIAGEN Company)
Invitae Corporation
Recent Revenue History
Company Overview
Invivoscribe Technologies, Inc.
iRepertoire, Inc.
Knome Inc.
Laboratory Corporation of America (LabCorp)
Recent Revenue History
Company Overview
LaserGen, Inc.
LifeCodexx AG (Subsidiary of GATC Biotech AG)
Life Technologies Corporation (Acquired by Thermo Fischer Scientific Inc.)
Recent Revenue History
Company Overview
Mayo Medical Laboratories and Mayo Clinic
MolecularMD Corporation
Multiplicom NV
Nabsys, Inc.
Natera, Inc.
NeoGenomics, Inc./NeoGenomics Laboratories
Recent Revenue History
Company Overview
NetBio, Inc
NewGene Ltd.
NextCODE Health
NobleGen Biosciences, Inc.
N-of-One, Inc.
OncoDNA SA
OncoPlex Diagnostics (OncoPlexDx)
Oncospire Genomics
One Lambda, Inc. (A Thermo Fisher Scientific Brand)
Oxford Gene Technology
Oxford Nanopore Technologies Ltd.
Pacific Biosciences
Recent Revenue History
Company Overview
Parabase Genomics
Pathway Genomics Corporation
PerkinElmer, Inc.
Recent Revenue History
Company Overview
Personal Genome Diagnostics, Inc.
Personalis, Inc.
PicoSeq
Population Genetics Technologies Ltd
QIAGEN N.V.
Recent Revenue History
Company Overview
QuantuMDx Group
Quest Diagnostics
Recent Revenue History
Company Overview
RainDance Technologies, Inc.
Response Genetics, Inc.
Recent Revenue History
Company Overview
Roche
Recent Revenue History
Company Overview
SeqLL, LLC
Sequenta, Inc
Siemens Healthcare Diagnostics
Siemens
Recent Revenue History
Company Overview
Sirona Genomics
SoftGenetics, LLC
Stratos Genomics Inc.
Swift Biosciences, Inc.
Symbiodx
Sysmex Inostics GmbH
Thermo Fisher Scientific, Inc.
Recent Revenue History
Company Overview
Vela Diagnostics
WaferGen Biosystems, Inc.
Recent Revenue History
Company Overview
ZS Genetics, Inc.
Overview
Scope and Methodology
Market Overview
Prognosis for Growth of the DNA Sequencing Market
TWO: INTRODUCTION
Overview and History of DNA Sequencing
Point-of-View
THREE: SEQUENCING TECHNOLOGY
Sanger Sequencing
Next-Generation Sequencing
Massively Parallel Signature Sequencing (MPSS)
Pyrosequencing
454 TECHNOLOGY
Sequencing by Synthesis (SBS)
Supported Oligonucleotide Ligation and Detection (SOLiD)
Ion Torrent Sequencing
True Single Molecule Sequencing (tSMS)
Single Molecule Real Time (SMRT) Sequencing
DNA Nanoball Sequencing
Nanopore Sequencing
Other Sequencing Technologies
Sample Preparation
Information Technology
Sample-to-Answer Workflows or Platforms
FOUR: SEQUENCING APPLICATIONS
Research, Drug Discovery and Development
Diagnostic Applications of Sequencing
Cancer Diagnostics
Genetic Analysis – Inherited Disorders, Prenatal Diagnostics, Postnatal Diagnostics
Infectious Disease Diagnostics
Human Leukocyte Antigen (HLA) Testing
Other Diagnostic Applications of Sequencing
Direct-to-Consumer Genetic Testing Industry
FIVE: DEALS – SEQUENCING COMPANIES
Investments and Financing Agreements for Sequencing Companies
Agreements with Other Companies
Acquisitions of Sequencing Companies
Selected Other Agreements
SIX: APPLYING SEQUENCING TO DIAGNOSTICS – MARKET DRIVERS AND CHALLENGES
Overcoming Technology Hurdles – Sample Preparation and Data Analysis
Next Generation Sequencing Market Drivers
Issues and Hurdles Faced by Companies Selling to the Research Market
Issues and Hurdles Faced by Companies in the Diagnostics Market
Future Prospects
SEVEN: DNA SEQUENCING MARKET ANALYSIS
DNA Sequencing Market Overview
Sequencing Market – Geographical Distribution
Brand Ownership
DNA Sequencing Market – Research versus Clinical Applications
EIGHT: COMPANY PROFILES: NEXT GENERATION SEQUENCING COMPANIES
10X GENOMICS
23ANDME, INC.
Adaptive Biotechnologies Corporation
Admera Health (A GENEWIZ Company)
Advanced Biological Laboratories, S.A
Agilent Technologies Inc.
Recent Revenue History
Company Overview
AltheaDx Diagnostics, Inc.
Ambry Genetics Corp.
Aperiomics, Inc.
Appistry, Inc.
Asuragen, Inc.
Diagnostic Products
Genomic Services
Clinical Lab
Companion Diagnostics
Athena Diagnostics, Inc. (A Quest Diagnostics Business)
Base4 Innovation Ltd
Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
Recent Revenue History
Company Overview
Next-Generation Sequencing - Sample Prep
Beckman Coulter Genomics
BGI-Shenzhen
Bina Technologies, Inc. (Acquired by Roche)
BioDiscovery, Inc.
Bioinnovation Solutions SA
Biomatters Ltd.
bioMérieux SA
Recent Revenue History
Company Overview
bioTheranostics (A bioMérieux Company)
Cancer Genetics, Inc.
Recent Revenue History
Company Overview
CareDx, Inc.
Recent Revenue History
Company Overview
Caris Life Sciences
Chronix Biomedical, Inc.
CLC bio (A QIAGEN Company)
Complete Genomics (A BGI Company)
Courtagen Life Sciences, Inc.
Cypher Genomics, Inc
DioGenix, Inc.
DNA Electronics Ltd.
DNASTAR, Inc.
Eurofins Genomics
Eurofins MWG Operon Inc. (A Eurofins Genomics Company)
Expression Analysis, Inc. (A Quintiles Company)
Fluidigm Corporation
Recent Revenue History
Company Overview
Foundation Medicine, Inc.
Recent Revenue History
Company Overview
GATC Biotech AG
GenapSys
GenDx
Gene by Gene, Ltd.
Genection, Inc. (An Invivoscribe Company)
GeneDx
GeneInsight, Inc.
GENEWIZ Inc.
Genia Technologies, Inc. (Acquired by Roche)
GenoLogics Life Sciences Software
Genomic Diagnostics Technologies
GenomOncology
Genoptix (A Novartis Company)
GigaGen, Inc.
GnuBIO, Inc. (Acquired by Bio-Rad Laboratories, Inc.)
Good Start Genetics, Inc.
HTG Molecular Diagnostics
Human Longevity, Inc.
Igenbio, Inc.
Illumina, Inc.
Recent Revenue History
Company Overview
Innovations Exchange Pte Ltd (INEX)
iGene Diagnostics Pte Ltd (an INEX Company)
Insight Genetics, Inc.
InSilixa, Inc.
Intel Corporation
Recent Revenue History
Company Overview
Intelligent Bio-Systems, Inc. (A QIAGEN Company)
Invitae Corporation
Recent Revenue History
Company Overview
Invivoscribe Technologies, Inc.
iRepertoire, Inc.
Knome Inc.
Laboratory Corporation of America (LabCorp)
Recent Revenue History
Company Overview
LaserGen, Inc.
LifeCodexx AG (Subsidiary of GATC Biotech AG)
Life Technologies Corporation (Acquired by Thermo Fischer Scientific Inc.)
Recent Revenue History
Company Overview
Mayo Medical Laboratories and Mayo Clinic
MolecularMD Corporation
Multiplicom NV
Nabsys, Inc.
Natera, Inc.
NeoGenomics, Inc./NeoGenomics Laboratories
Recent Revenue History
Company Overview
NetBio, Inc
NewGene Ltd.
NextCODE Health
NobleGen Biosciences, Inc.
N-of-One, Inc.
OncoDNA SA
OncoPlex Diagnostics (OncoPlexDx)
Oncospire Genomics
One Lambda, Inc. (A Thermo Fisher Scientific Brand)
Oxford Gene Technology
Oxford Nanopore Technologies Ltd.
Pacific Biosciences
Recent Revenue History
Company Overview
Parabase Genomics
Pathway Genomics Corporation
PerkinElmer, Inc.
Recent Revenue History
Company Overview
Personal Genome Diagnostics, Inc.
Personalis, Inc.
PicoSeq
Population Genetics Technologies Ltd
QIAGEN N.V.
Recent Revenue History
Company Overview
QuantuMDx Group
Quest Diagnostics
Recent Revenue History
Company Overview
RainDance Technologies, Inc.
Response Genetics, Inc.
Recent Revenue History
Company Overview
Roche
Recent Revenue History
Company Overview
SeqLL, LLC
Sequenta, Inc
Siemens Healthcare Diagnostics
Siemens
Recent Revenue History
Company Overview
Sirona Genomics
SoftGenetics, LLC
Stratos Genomics Inc.
Swift Biosciences, Inc.
Symbiodx
Sysmex Inostics GmbH
Thermo Fisher Scientific, Inc.
Recent Revenue History
Company Overview
Vela Diagnostics
WaferGen Biosystems, Inc.
Recent Revenue History
Company Overview
ZS Genetics, Inc.
LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY
Table 1-1: Worldwide Sequencing Market Product Revenues (Instruments and Consumables), 2014 and 2019
Figure 1-1: Worldwide Sequencing Market Product Revenues (Instruments and Consumables), 2014 and 2019
THREE: SEQUENCING TECHNOLOGY
Table 3-1: Sequencing Technologies and Platforms
Table 3-2: Selected Companies Developing/Marketing Products for NGS Sample Preparation
Table 3-3: Selected Companies Developing/Marketing NGS Information Technology Solutions
Table 3-4: Selected Companies Developing NGS Sample-to-Answer Platforms
FOUR: SEQUENCING APPLICATIONS
Table 4-1: Selected Companies Developing or Marketing Next Generation Sequencing Products or Services for Research Applications
Table 4-2: Selected Pharmaceutical Companies That Made Deals to Access Next Generation Sequencing Technologies or Capabilities
Table 4-3: Selected Diagnostic Companies Offering Sequencing-Based Tests through Their Own CLIA-Certified Laboratory and Selected Reference Laboratories Offering Sequencing-Based Tests
Table 4-4: Selected Diagnostic Companies Developing or Marketing Sequencing-Based Tests as Kits Sold to Clinical Laboratories
Table 4-5: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Oncology
Table 4-6: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Genetic Analysis (Inherited Disorders, Prenatal and Postnatal Diagnostics)
Table 4-7: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Infectious Diseases
Table 4-8: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Human Leukocyte Antigen (HLA) Testing
Table 4-9: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Other Diagnostic Applications
FIVE: DEALS – SEQUENCING COMPANIES
Table 5-1: Selected Investment and Other Financing Agreements for Next Generation Sequencing Companies (Includes IT Companies in NGS)
Table 5-2: Selected Agreements between Next Generation Sequencing Companies and Other Diagnostic Companies or Clinical Laboratories (Includes IT Companies in NGS)
Table 5-3: Selected Agreements between Next Generation Sequencing Companies and Pharmaceutical or Biopharmaceutical Companies (Includes Contract Research Organizations Providing Services to Pharma Companies)
Table 5-4: Selected Company Agreements between Two Next Generation Sequencing Companies (Includes IT Companies in NGS)
Table 5-5: Selected Other Next-Generation Sequencing Company Agreements(Includes IT Companies in NGS)
Table 5-6: Selected Acquisitions of Next Generation Sequencing Companies(Includes IT Companies in NGS)
Table 5-7: Selected Next Generation Sequencing Company Agreements with Academic or Other Non-Profit Organizations (Includes IT Companies in NGS)
SEVEN: DNA SEQUENCING MARKET ANALYSIS
Table 7-1: Instrument Revenue, DNA Sequencing Market, Worldwide, 2014 and 2019
Table 7-2: Consumables Revenue, DNA Sequencing Market, Worldwide, 2014 and 2019
Table 7-3: Services Revenue, DNA Sequencing Market, Worldwide, 2014 and 2019
Table 7-4: Total DNA Sequencing Market, Worldwide, 2014 and 2019
Figure 7-1: Next Generation Sequencing Market (Instruments, Consumables, Systems), 2014 vs. 2019
Figure 7-2: Market Share of DNA Sequencing Market, by Company
Table 7-5: DNA Sequencing Revenues by Geographical Region, Worldwide, 2014 and 2019 (North America, Europe, Asia, Rest of World, Total Market)
Figure 7-3: Next Generation Sequencing System Ownership by Country, Percentage(United States, China, Germany, UK, South Korea, Spain, Canada, France, Australia,Netherlands, Italy, Taiwan, Brazil, Japan, India, Sweden, Belgium, Denmark, Switzerland, Singapore, Saudi Arabia, Others)
Figure 7-4: Next Generation Sequencing System Ownership by Brand (HiSeq2000, Genome Analyser, Roche 454, ABI SOLiD, Ion Torrent, MiSeq, Ion Proton, Pacific Biosciences, Oxford Nanopore MinION, Polonator, NextSeq)
Figure 7-5: DNA Sequencing Market – Research versus Clinical Applications,2014
ONE: EXECUTIVE SUMMARY
Table 1-1: Worldwide Sequencing Market Product Revenues (Instruments and Consumables), 2014 and 2019
Figure 1-1: Worldwide Sequencing Market Product Revenues (Instruments and Consumables), 2014 and 2019
THREE: SEQUENCING TECHNOLOGY
Table 3-1: Sequencing Technologies and Platforms
Table 3-2: Selected Companies Developing/Marketing Products for NGS Sample Preparation
Table 3-3: Selected Companies Developing/Marketing NGS Information Technology Solutions
Table 3-4: Selected Companies Developing NGS Sample-to-Answer Platforms
FOUR: SEQUENCING APPLICATIONS
Table 4-1: Selected Companies Developing or Marketing Next Generation Sequencing Products or Services for Research Applications
Table 4-2: Selected Pharmaceutical Companies That Made Deals to Access Next Generation Sequencing Technologies or Capabilities
Table 4-3: Selected Diagnostic Companies Offering Sequencing-Based Tests through Their Own CLIA-Certified Laboratory and Selected Reference Laboratories Offering Sequencing-Based Tests
Table 4-4: Selected Diagnostic Companies Developing or Marketing Sequencing-Based Tests as Kits Sold to Clinical Laboratories
Table 4-5: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Oncology
Table 4-6: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Genetic Analysis (Inherited Disorders, Prenatal and Postnatal Diagnostics)
Table 4-7: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Infectious Diseases
Table 4-8: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Human Leukocyte Antigen (HLA) Testing
Table 4-9: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Other Diagnostic Applications
FIVE: DEALS – SEQUENCING COMPANIES
Table 5-1: Selected Investment and Other Financing Agreements for Next Generation Sequencing Companies (Includes IT Companies in NGS)
Table 5-2: Selected Agreements between Next Generation Sequencing Companies and Other Diagnostic Companies or Clinical Laboratories (Includes IT Companies in NGS)
Table 5-3: Selected Agreements between Next Generation Sequencing Companies and Pharmaceutical or Biopharmaceutical Companies (Includes Contract Research Organizations Providing Services to Pharma Companies)
Table 5-4: Selected Company Agreements between Two Next Generation Sequencing Companies (Includes IT Companies in NGS)
Table 5-5: Selected Other Next-Generation Sequencing Company Agreements(Includes IT Companies in NGS)
Table 5-6: Selected Acquisitions of Next Generation Sequencing Companies(Includes IT Companies in NGS)
Table 5-7: Selected Next Generation Sequencing Company Agreements with Academic or Other Non-Profit Organizations (Includes IT Companies in NGS)
SEVEN: DNA SEQUENCING MARKET ANALYSIS
Table 7-1: Instrument Revenue, DNA Sequencing Market, Worldwide, 2014 and 2019
Table 7-2: Consumables Revenue, DNA Sequencing Market, Worldwide, 2014 and 2019
Table 7-3: Services Revenue, DNA Sequencing Market, Worldwide, 2014 and 2019
Table 7-4: Total DNA Sequencing Market, Worldwide, 2014 and 2019
Figure 7-1: Next Generation Sequencing Market (Instruments, Consumables, Systems), 2014 vs. 2019
Figure 7-2: Market Share of DNA Sequencing Market, by Company
Table 7-5: DNA Sequencing Revenues by Geographical Region, Worldwide, 2014 and 2019 (North America, Europe, Asia, Rest of World, Total Market)
Figure 7-3: Next Generation Sequencing System Ownership by Country, Percentage(United States, China, Germany, UK, South Korea, Spain, Canada, France, Australia,Netherlands, Italy, Taiwan, Brazil, Japan, India, Sweden, Belgium, Denmark, Switzerland, Singapore, Saudi Arabia, Others)
Figure 7-4: Next Generation Sequencing System Ownership by Brand (HiSeq2000, Genome Analyser, Roche 454, ABI SOLiD, Ion Torrent, MiSeq, Ion Proton, Pacific Biosciences, Oxford Nanopore MinION, Polonator, NextSeq)
Figure 7-5: DNA Sequencing Market – Research versus Clinical Applications,2014
